RECRUITING

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.

Official Title

PATROL: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

Quick Facts

Study Start:2020-05-21
Study Completion:2030-08-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04472338

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * People with prostates ≥40 years of age
  2. * Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk.
  1. * Prior diagnosis of prostate cancer
  2. * Medical contraindication to any of the study procedures (e.g., prostate biopsy)
  3. * For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy)
  4. * Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk
  5. * Unable to provide written informed consent
  6. * Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.

Contacts and Locations

Study Contact

Study Team Coordinator
CONTACT
206-210-4040
patrol@uw.edu

Principal Investigator

Heather H. Cheng, MD, PhD
PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium

Study Locations (Sites)

City of Hope
Duarte, California, 91010
United States
University of California, San Francisco
San Francisco, California, 94143
United States
Northwestern
Chicago, Illinois, 60611
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
OHSU Knight Cancer Institute
Portland, Oregon, 97239
United States
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104
United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229
United States
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109
United States

Collaborators and Investigators

Sponsor: University of Washington

  • Heather H. Cheng, MD, PhD, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-05-21
Study Completion Date2030-08-31

Study Record Updates

Study Start Date2020-05-21
Study Completion Date2030-08-31

Terms related to this study

Additional Relevant MeSH Terms

  • Prostate Carcinoma